Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops

Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth... Int Ophthalmol (2018) 38:1193–1204 https://doi.org/10.1007/s10792-017-0582-7 ORIGINAL PAPER Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops . . . Ronald Mauricio Sanchez-Avila Jesus Merayo-Lloves Ana Cristina Riestra . . . Luis Fernandez-Vega Cueto Eduardo Anitua Leire Begona Francisco Muruzabal Gorka Orive Received: 26 August 2016 / Accepted: 5 June 2017 / Published online: 15 June 2017 Springer Science+Business Media B.V. 2017 Abstract and Visual Analogue Scale (VAS) were also evaluated Purpose To provide preliminary data about efficacy before and after treatment with PRGF. The influence and safety of plasma rich in growth factors (PRGF) of some patients’ clinical variables on results was eye-drops in neurotrophic keratitis (NK) and to assessed. Safety assessment was also performed analyze the possible influence of certain variables on reporting all adverse events. treatment outcomes. Results Thirty-eight treated eyes in a total of thirty- Methods This retrospective study included patients one patients were evaluated, of which five cases had no with stages 2–3 of NK treated with PRGF eye-drops. prior response to autologous serum treatment. Most Primary endpoint was the resolution time of corneal cases (97.4%) achieved the complete resolution of ulcer defect. Outcome measures including http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Ophthalmology Springer Journals

Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops

Loading next page...
 
/lp/springer_journal/treatment-of-patients-with-neurotrophic-keratitis-stages-2-and-3-with-LKs1ZU4Fpz

References (40)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media B.V.
Subject
Medicine & Public Health; Ophthalmology
ISSN
0165-5701
eISSN
1573-2630
DOI
10.1007/s10792-017-0582-7
pmid
28620707
Publisher site
See Article on Publisher Site

Abstract

Int Ophthalmol (2018) 38:1193–1204 https://doi.org/10.1007/s10792-017-0582-7 ORIGINAL PAPER Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops . . . Ronald Mauricio Sanchez-Avila Jesus Merayo-Lloves Ana Cristina Riestra . . . Luis Fernandez-Vega Cueto Eduardo Anitua Leire Begona Francisco Muruzabal Gorka Orive Received: 26 August 2016 / Accepted: 5 June 2017 / Published online: 15 June 2017 Springer Science+Business Media B.V. 2017 Abstract and Visual Analogue Scale (VAS) were also evaluated Purpose To provide preliminary data about efficacy before and after treatment with PRGF. The influence and safety of plasma rich in growth factors (PRGF) of some patients’ clinical variables on results was eye-drops in neurotrophic keratitis (NK) and to assessed. Safety assessment was also performed analyze the possible influence of certain variables on reporting all adverse events. treatment outcomes. Results Thirty-eight treated eyes in a total of thirty- Methods This retrospective study included patients one patients were evaluated, of which five cases had no with stages 2–3 of NK treated with PRGF eye-drops. prior response to autologous serum treatment. Most Primary endpoint was the resolution time of corneal cases (97.4%) achieved the complete resolution of ulcer defect. Outcome measures including

Journal

International OphthalmologySpringer Journals

Published: Jun 15, 2017

There are no references for this article.